These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28618224)

  • 1. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
    Ma H; Lu W; Sun Z; Luo L; Geng D; Yang Z; Li E; Zheng J; Wang M; Zhang H; Yang S; Zhang X
    Eur J Med Chem; 2015 Jan; 89():721-32. PubMed ID: 25462278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization on a virtual screening hit of smoothened receptor.
    Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
    Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
    Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
    PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
    Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
    Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
    Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
    Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
    Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
    Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
    Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
    Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E1 Inhibits
    Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
    Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
    Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
    FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
    Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.